Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (181)	3/20/2002 4:32:14 PM
From: Arthur Radley	Read Replies (1) of 631

Another failure in the psoriasis area.. Protein Design psoriasis drug fails in tests FREMONT, Calif., March 20 (Reuters) - Protein Design Labs Inc. (NasdaqNM:PDLI - news) on Wednesday said its psoriasis treatment failed to meet its main goal in trials. The company said Phase II tests of its Zenapax treatment for patients with moderate-to-severe psoriasis following treatment with cyclosporine did not prolong the time to recurrence of psoriasis, the main target of the trial. Protein Design said it plans to end development of Zenapax as a treatment for psoriasis in conjunction with cyclosporine but could decide to pursue other development options for the drug, known by the chemical name daclizumab, in psoriasis. ``We do plan to continue to explore the use of daclizumab in other indications, and currently there are trials under way in asthma, multiple sclerosis, type I diabetes and uveitis,'' the company said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next